Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
Steady: 0 in the last 7 days
Updated oct 6
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BMS faces patent/generic pressure while a Growth Portfolio generates significant revenue.1 source
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Sub-event
Industry-wide patent cliff and investment pressure hits major pharma firms.1 source
Keep exploring
The entities involved
-
Merck KGaA
German multinational science and technology company
-
Moderna
American biotechnology company
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- insidermonkey.com
- Pharma VoiceBiopharma layoffs rise as drugmakers tighten belts and reorganize This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsl
- Motley Fool2 Top Stocks Down 16% and 17% This Year to Buy and Hold Merck and Bristol Myers Squibb are facing challenges due to recent (and future) patent cliffs. Both drugmakers have deep pipelines that could a